




ELSEVIER

Contents lists available at ScienceDirect

## Domestic Animal Endocrinology

journal homepage: [www.journals.elsevier.com/domestic-animal-endocrinology](http://www.journals.elsevier.com/domestic-animal-endocrinology)

## Short Communication: Identification of equine corticotropin-like intermediate lobe peptide (CLIP) binding to an adrenocorticotrophic hormone (ACTH) assay capture antibody

E.J. Knowles<sup>a,\*</sup>, C. Hyde<sup>b</sup>, P.A. Harris<sup>c</sup>, J. Elliott<sup>d</sup>, N.J. Menzies-Gow<sup>a</sup><sup>a</sup>The Royal Veterinary College, Hawkshead Lane, Hatfield, Herts AL9 7TA, UK<sup>b</sup>Bio-Analysis Centre, 2 Royal College St, London NW1 0NH, UK<sup>c</sup>Waltham Petcare Science Institute, Waltham on the Wold, LE14 4RT<sup>d</sup>The Royal Veterinary College, Royal College Street, London, NW1 0TU, UK

## ARTICLE INFO

## Article history:

Received 2 December 2022

Received in revised form 7 January 2023

Accepted 10 January 2023

Available online xxx

## Keywords:

ACTH

CLIP

Pituitary *pars-intermedia* dysfunction

Equine

## ABSTRACT

A chemiluminescent immunoassay is commonly employed to measure adrenocorticotrophic hormone (ACTH) concentrations to assist pituitary *pars intermedia* dysfunction diagnosis. In a previous study, seasonally dependent assay cross-reactivity to endogenous equine corticotropin-like intermediate lobe peptide (CLIP, ACTH 18–39) was suspected. The present study aimed to demonstrate binding of endogenous equine CLIP to the capture antibody of the ACTH chemiluminescent immunoassay. Liquid chromatography – mass spectrometry (LCMS) methods were optimised to identify selected ions from synthetic human ACTH,  $\alpha$ -melanocyte stimulating hormone ( $\alpha$ -MSH, ACTH 1–17) and CLIP. Synthetic ACTH and CLIP bound to the capture antibody of the chemiluminescent ACTH assay, but  $\alpha$ -MSH did not. Equine endogenous CLIP was detected by LCMS in pony plasma taken in the autumn and could be eluted from the capture antibody of the ACTH chemiluminescent immunoassay. Further research is required to enable quantification of CLIP. Equine CLIP may alter measured ACTH concentrations *in vivo*.

© 2023 Published by Elsevier Inc.

## 1. Introduction

Equine pituitary *pars intermedia* dysfunction (PPID) is a common neurodegenerative disease often diagnosed using adrenocorticotrophic hormone (ACTH) concentrations measured by a chemiluminescent sandwich immunoassay (Immulite/ Immulite 1000 ACTH, Siemens). The assay's monoclonal capture antibody is raised to human corticotrophin-like intermediate lobe peptide (CLIP), a-C-terminal fragment of ACTH (ACTH 18–39) and is immobilized onto a plastic bead contained within a reaction cup; the detection (polyclonal) antibody is raised to ACTH

12 (personal communication, Siemens UK). In a previ- 12  
ous study, this ACTH assay showed suspected seasonally- 13  
dependent cross-reactivity when analyzing equine samples 14  
[1]. When the results of 2 ACTH assays were compared, 15  
samples collected in the spring showed a small bias be- 16  
tween the 2 assays, whereas samples collected in the au- 17  
tumn showed a marked bias with wide limits of agree- 18  
ment [1]. The package insert for the ACTH chemilumines- 19  
cent assay reports 13% to 15% cross-reactivity to CLIP, al- 20  
though the species and matrix are not specified. In ex- 21  
perimental work, the addition of human synthetic CLIP 22  
to equine plasma revealed 9% to 21% cross-reactivity [1]. 23  
Equine endogenous CLIP is therefore a candidate *in vivo* 24  
cross-reactant, although it is unknown whether endoge- 25  
nous CLIP is present at detectable concentrations in appar- 26  
ently normal equids nor whether endogenous CLIP shows 27

\* Corresponding author. Tel.

E-mail address: [ejknowles@rvc.ac.uk](mailto:ejknowles@rvc.ac.uk) (E.J. Knowles).

**Table 1**Optimised LCMS conditions for detection of ACTH,  $\alpha$ -MSH and CLIP.

Column Type	Aeris XB-C8
Column Dimensions	100 $\times$ 2.1 mm
Gradient	5- 21% B, 3.5 mins
Mobile phase A	0.1% Formic Acid in Water
Mobile Phase B	0.1% Formic Acid in Acetonitrile:Methanol:IPA (1:1:1)
Column oven temperature	85°C
Autosampler Temperature	15°C
Nebulising Gas flow	3L/min
DL temperature	250°C
Heat Block temperature	400°C
Drying gas flow	15 L/min
Total Run time	15 min

28 similar cross-reactivity to synthetic CLIP. The predicted sequence of equine ACTH [2] is identical to human ACTH [3], however partial sequence transcriptome analysis suggests sequence differences [4]. Endogenous human ACTH includes 3 post-translationally modified residues [3]. Endogenous equine ACTH (and CLIP) may therefore interact differently with assay antibodies compared with synthetic peptides based on human sequences.

36 The present study aimed to determine whether synthetic human CLIP and endogenous equine CLIP bind to the capture antibody of the chemiluminescent ACTH assay.

## 39 2. Materials and methods

40 Ethical approval was obtained from the Royal Veterinary College Ethics and Welfare Committee. The study was conducted under a UK Home Office license (PPL 70/8195) as the study used surplus plasma from 12, non-laminitis British native ponies enrolled in another study.

45 Liquid chromatography-mass spectrometry (LCMS) (LCMS8040, Shimadzu) was used for analysis. Methods were optimized for detection of synthetic human ACTH,  $\alpha$ -MSH and CLIP (A0423, M4135 and A0673 Sigma- Aldrich) in distilled water at supra-physiological concentrations (60ng/ml). The most abundant detectable ions were identified for subsequent selective ion monitoring (SIM). Interactions between the synthetic peptide solutions and the assay capture antibody were determined by analysis of solutions of each peptide prior to and following incubation with the antibody bound beads and following washing and elution of the peptide from the beads. (Table 1)

57 The elution process was optimized as follows: 750 $\mu$ l of synthetic peptide solution (60ng/ml) was mixed with 250 $\mu$ l of Reagent 1 (a buffer) from the chemiluminescent ACTH assay reagent kit and added to 5 antibody bound beads in a syringe barrel. The syringe was mixed for 30 min at 250 rpm on an orbital shaker. The solution was removed under vacuum. The 5 beads were washed twice with 2ml water for 30 min each. Finally, 500 $\mu$ l of an elution solution (see below) was added and the syringe and mixed for a further 30 minutes at 250rpm on an orbital shaker. The resulting solution was transferred to a tube by a vacuum manifold, dried under nitrogen and reconstituted in 100 $\mu$ l of distilled water prior to analysis by LCMS. For initial trials 0.1M glycine: HCl was used for elution how-

**Table 2**

Mass to charge ratio (m/z), detection time for each ion (dwell time) and optimized quadrupole energy (Q3 bias) for the most abundant detectable ions from synthetic peptides based on human sequences used for subsequent analysis.

Peptide	m/z	Dwell time (msec)	Q3 bias (V)
ACTH	909.1	100	-26
	757.5	100	-38
	649.7	100	-32
CLIP	822.6	10	
	1233.3	10	
$\alpha$ -	555.7	10	
MSH	833	10	

ever this damaged the chromatography column and subsequent analysis used a solution of 1% formic acid in water: acetonitrile (1:1). Conditions for elution are summarized in Table 2.

To investigate the binding of endogenous CLIP, EDTA plasma from samples taken from 12 ponies in the autumn was used to create 2 pools with high and low measured ACTH concentrations using the chemiluminescent assay. Pooled plasma samples were incubated with the antibody-bound beads. Elution and LCMS detection of equine endogenous ACTH and CLIP was compared with results obtained from charcoal stripped equine plasma [5] spiked with synthetic ACTH and CLIP.


## 3. Results

The most readily detectable ions from initial analysis of synthetic ACTH,  $\alpha$ -MSH and CLIP are shown in Table 2. The solutions of synthetic  $\alpha$ -MSH, ACTH and CLIP in distilled water overloaded the binding capacity of the antibody-bound beads. After incubation with the bead, most of the peptide remained in solution but there was a reduction in the peaks for CLIP and ACTH but not  $\alpha$ -MSH, indicating binding of ACTH and CLIP but not  $\alpha$ -MSH.


The high and low pools of equine plasma yielded ACTH results of 232pg/ml and 25.7pg/ml respectively when analyzed using the chemiluminescent immunoassay according to the manufacturer's instructions. LCMS SIM analysis identified endogenous ACTH and CLIP in eluted solutions created from both pools, with higher concentrations of both analyzes in the high pool (Figs. 1 and 2). The twin-peaked appearance of the chromatograms may indicate different conformational forms of the peptides. Unfortunately, these analyzes could not be quantified accurately because the mass range of the LCMS analyzer is 1-2000Da, such that the molecular ions of ACTH and CLIP were too large to be detected, limiting sensitivity.

## 4. Discussion

To cause the previously reported cross-reactivity [1], synthetic CLIP must bind both the assay capture and detection antibodies of the ACTH chemiluminescent immunoassay. The present data confirm that synthetic CLIP binds to the capture antibody. In addition, one or more CLIP-like endogenous peptides are present in plasma collected from ponies in the autumn and bind to the capture antibody.



**Fig. 1.** Chromatogram of selected equine ACTH ions following LCMS analysis of pony plasma spiked with: synthetic ACTH (black line) and low (magenta line) and high (blue line) pooled pony plasma samples following elution from the chemiluminescent (CL) assay capture antibody. The y axis indicates signal intensity (counts), the x axis time (min). The low and high pools yielded apparent ACTH concentrations of 25.2pg/ml and 232pg/ml respectively. (For interpretation of the references to color in this figure legend, the reader is referred to the Web version of this article.)



**Fig. 2.** Chromatogram of selected equine CLIP ions following LCMS analysis of pony plasma spiked with: synthetic CLIP (black line) and low (magenta line) and high (dark blue line) pooled pony plasma following elution from the chemiluminescent (CL) assay capture antibody. The y axis indicates signal intensity (counts), the x axis time (min). The low and high pools yielded apparent ACTH concentrations of 25.2pg/ml and 232pg/ml respectively. (For interpretation of the references to color in this figure legend, the reader is referred to the Web version of this article.)

114 tibility. Given that CLIP is the antibody target (Siemens  
115 UK, personal communication) this binding was anticipated  
116 but has not been demonstrated previously for endogenous  
117 equine CLIP in equine plasma. Whilst the exact mechanism  
118 of cross-reactivity was not determined, it is speculated that  
119 this results from the overlap between the antibody targets;  
120 the 6 N-terminal residues of CLIP (ACTH 18–24) may be  
121 an epitope for the polyclonal detection antibody raised to  
122 ACTH 1 to 24 (Siemens, personal communication). It is pre-  
123 sumed therefore that the epitope for the capture antibody  
124 lies in the 24 to 39 residue region.

125 Previous studies have also indicated the presence of an  
126 endogenous cross-reactant in pony plasma in basal plasma  
127 samples collected in the autumn [1] and following *pars in-*  
128 *termedia* stimulation with exogenous thyrotropin-releasing  
129 hormone (TRH) [6] that is present at sufficiently high con-  
130 centrations to affect the results of diagnostic tests. The  
131 present study supports the suggestion that endogenous  
132 CLIP is that cross-reactant and may alter measured ACTH  
133 concentrations *in vivo*, however binding by endogenous  
134 CLIP to the detection antibody has not been conclusively  
135 demonstrated.

The potential for equine CLIP to increase measured  
ACTH concentrations raises several questions including the  
potential for other CLIP-like peptides to exert similar ef-  
fects. A seasonal pattern of measured equine ACTH con-  
centrations occurs as a physiological process and, in an  
exaggerated manner, in equids with PPID [7]. The extent  
to which the seasonal autumnal increase and the patho-  
logical increases measured in PPID are caused by CLIP  
rather than ACTH requires investigation. It is also unclear  
whether CLIP has direct metabolic effects in the horse. In  
rats, CLIP exerts orexigenic effects during fasting [8] and the  
CLIP metabolite  $\beta$ -Cell tropin is a potent insulin secreta-  
gogue [9] with a more potent secretogenic effect on fatty  
rather than lean rat pancreas [10]. Although speculative,  
the clinical implications would be important if CLIP or  $\beta$ -  
Cell tropin were to exert similar effects in the horse.

## 5. Conclusions

Circulating equine endogenous CLIP can be detected by  
LCMS in plasma from healthy ponies sampled in the au-  
tumn and binds to the capture antibody of a commonly

156 used chemiluminescent immunoassay. This finding pro- 185  
 157 vides further support for the hypothesis that endogenous 186  
 158 CLIP affects measured ACTH concentrations *in vivo* which 187  
 159 may have implications for our understanding of the diag- 188  
 160 nosis and pathophysiology of PPID. 189

## 161 **Uncited References**

162 [11]

## 163 **Acknowledgments**

164 The study received funding from: Petplan Charitable 200  
 165 Trust and MARS Petcare UK. E.J. Knowles' PhD was also 201  
 166 supported by The Mellon Trust. There are no conflicts of 202  
 167 interest for any of the authors. 203

168 The authors thank Michelle Moreton Clack for labora- 204  
 169 tory assistance and visiting students for assistance with 205  
 170 sample collection. 206

## 171 **CRediT authorship contribution statement**

172 **E.J. Knowles:** Conceptualization, Funding acquisition, 207  
 173 Writing – original draft, Investigation. **C. Hyde:** Method- 208  
 174 ology, Investigation, Data curation, Visualization, Writing 209  
 175 – review & editing. **P.A. Harris:** Supervision, Writing – 210  
 176 review & editing, Funding acquisition. **J. Elliott:** Supervi- 211  
 177 sion, Writing – review & editing, Funding acquisition. **N.J.** 212  
 178 **Menzies-Gow:** Funding acquisition, Project administration, 213  
 179 Supervision, Writing – review & editing. 214

## 180 **References**

181 [1] Knowles EJ, Shaw S, Harris PA, Elliott J. Plasma adrenocorticotrophic 215  
 182 hormone (ACTH) concentrations in ponies measured by two different 216  
 183 assays suggests seasonal cross-reactivity or interference. *Equine Vet* 217  
 184 *J* 2018;50:672–7. doi:10.1111/evj.12797. 218

- [2] The Uniprot Consortium. UniProt accession number F6W8H2 n.d. 185  
<https://www.uniprot.org/uniprotkb/F6W8H2/entry> accessed October 186  
 18, 2022. 187
- [3] The Uniprot Consortium. Uniprot accession number P01189 n.d. 188  
<https://www.uniprot.org/uniprotkb/P01189/entry> accessed October 189  
 18, 2022. 190
- [4] Carmalt JL, Mortazavi S, McOnie RC, Allen AL, Unniappan S. Profiles 191  
 of pro-opiomelanocortin and encoded peptides, and their processing 192  
 enzymes in equine pituitary pars intermedia dysfunction. *PLoS One* 193  
 2018;13:1–11. doi:10.1371/journal.pone.0190796. 194
- [5] Borer-Weir KE, Bailey SR, Menzies-Gow NJ, Harris PA, Elliott J. Evalu- 195  
 ation of a commercially available radioimmunoassay and species- 196  
 specific ELISAs for measurement of high concentrations of insulin in 197  
 equine serum. *Am J Vet Res* 2012;73:1596–602. doi:10.2460/ajvr.73. 198  
 10.1596. 199
- [6] McGilvray TA, Knowles EJ, Harris PA, Menzies-Gow NJ. Comparison 200  
 of immunofluorescence and chemiluminescence assays for measur- 201  
 ing ACTH in equine plasma. *Equine Vet J* 2020;52:709–14. doi:10. 202  
 1111/evj.13227. 203
- [7] McFarlane D. Equine pituitary pars intermedia dysfunction. *Vet Clin* 204  
*North Am Equine Pract* 2011;27:93–113. doi:10.1016/j.cveq.2010.12. 205  
 007. 206
- [8] Al-Barazanjani KA, Miller JE, Rice SQ, Arch JR, Chambers JK. C-terminal 207  
 fragments of ACTH stimulate feeding in fasted rats. *Horm Metab* 208  
*Res = Horm Und Stoffwechselforsch = Horm Metab* 2001;33:480–5. 209  
 doi:10.1055/s-2001-16941. 210
- [9] Beloff-Chain A, Morton J, Dunmore S, Taylor GW, Morris HR. Evi- 211  
 dence that the insulin secretagogue, beta-cell-tropin, is ACTH22-39. 212  
*Nature* 1983;301:255–8. doi:10.1038/301255a0. 213
- [10] Dunmore SJ, Cawthorne MA, Hislop DC, Morton JL, Beloff-Chain A. 214  
 Beta-cell tropin- and glucose-induced hypersecretion of insulin and 215  
 amylin from perfused fatty rat pancreas. *J Endocrinol* 1993;137:375– 216  
 81. doi:10.1677/joe.0.1370375. 217
- [11] Watkinson A, Beloff-Chain A. The insulin-like action of  $\beta$ -Cell-Tropin 218  
 on glucose and lipid metabolism in adipocytes. *Horm Metab Res* 219  
 1984;16:55–8. doi:10.1055/s-2007-1014898. 220

221